Xueyun Zeng1, Mingjie Sui1, Rui Liu1, Xinyu Qian2, Wenfeng Li3, Erwei Zheng4, Jinjin Yang1, Jinmei Li5, Weidong Huang6, Hongbin Yang7, Hongjuan Yu8,9, Nan Luo2. 1. School of Health Management, Harbin Medical University, Harbin, 150086, China. 2. National University Singapore Saw Swee Hock School of Public Health, Singapore, 117549, Singapore. 3. Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. 4. First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. 5. Public Health Education and Information Center of Heilongjiang Province, Harbin, 150063, China. 6. School of Health Management, Harbin Medical University, Harbin, 150086, China. weidong218@126.com. 7. Department of Medical Oncology, Third Affiliated Hospital of Harbin Medical University, Harbin, 150081, China. Yang21hongbin@163.com. 8. Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. yuhongjuan2008@163.com. 9. Southern University of Science and Technology Hospital, Shenzhen, 518055, China. yuhongjuan2008@163.com.
Abstract
OBJECTIVES: This study aimed to assess the health utility of leukemia patients in China using the EQ-5D-5L, compare it with the population norms, and identify the potential factors associated with health utility. METHODS: A hospital based cross-sectional survey was conducted in three tertiary hospitals from July 2015 to February 2016. A total of 186 patients with leukemia completed the EQ-5D-5L and their health utility scores were calculated using the Chinese value set. EQ-5D-5L utility and dimensions scores of leukemia patients were compared with China's population norms using Kruskal-Wallis test and chi square test. Potential factors associated with health utility were identified using Tobit regression. RESULTS: The mean EQ-5D-5L utility scores of patients with leukemia, grouped by either gender or age, were significantly lower than those of the general population (p < 0.001). The same results were found for individual dimensions of EQ-5D-5L, where leukemia patients reported more health problems than the general population (p < 0.001). The utility score of leukemia patients was found to be significantly related to medical insurance, religious belief, comorbidities, social support and ECOG performance status. CONCLUSION: This study indicated that leukemia patients have worse health status compared to the general population of China and that multiple factors affect the health utility of the patients. The utility scores reported in this study could be useful in future cost-utility analysis.
OBJECTIVES: This study aimed to assess the health utility of leukemiapatients in China using the EQ-5D-5L, compare it with the population norms, and identify the potential factors associated with health utility. METHODS: A hospital based cross-sectional survey was conducted in three tertiary hospitals from July 2015 to February 2016. A total of 186 patients with leukemia completed the EQ-5D-5L and their health utility scores were calculated using the Chinese value set. EQ-5D-5L utility and dimensions scores of leukemiapatients were compared with China's population norms using Kruskal-Wallis test and chi square test. Potential factors associated with health utility were identified using Tobit regression. RESULTS: The mean EQ-5D-5L utility scores of patients with leukemia, grouped by either gender or age, were significantly lower than those of the general population (p < 0.001). The same results were found for individual dimensions of EQ-5D-5L, where leukemiapatients reported more health problems than the general population (p < 0.001). The utility score of leukemiapatients was found to be significantly related to medical insurance, religious belief, comorbidities, social support and ECOG performance status. CONCLUSION: This study indicated that leukemiapatients have worse health status compared to the general population of China and that multiple factors affect the health utility of the patients. The utility scores reported in this study could be useful in future cost-utility analysis.
Entities:
Keywords:
Cancer; EQ-5D-5L; Health utility; Leukemia
Authors: Sara R Alcorn; Michael J Balboni; Holly G Prigerson; Amy Reynolds; Andrea C Phelps; Alexi A Wright; Susan D Block; John R Peteet; Lisa A Kachnic; Tracy A Balboni Journal: J Palliat Med Date: 2010-05 Impact factor: 2.947
Authors: Fábio R M Santos; Elisa H Kozasa; Maria de Lourdes L F Chauffaille; Gisele W B Colleoni; Jose Roberto Leite Journal: J Psychosom Res Date: 2006-05 Impact factor: 3.006
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702